Korean J Urol.  2015 Jan;56(1):68-75. 10.4111/kju.2015.56.1.68.

Community-based research on the benign prostatic hyperplasia prevalence rate in Korean rural area

• Goh HJ
• Kim SA
• Nam JW
• Choi BY
• Moon HS

• KMID: 2070271
• DOI: http://doi.org/10.4111/kju.2015.56.1.68

Abstract

PURPOSE
We investigated the prevalence rate of benign prostatic hyperplasia (BPH) among Korean males in a rural area through a cross-sectional, community-based epidemiologic survey and analyzed the correlation with epidemiologic factors.
MATERIALS AND METHODS
A total of 779 males who lived in Yangpyeong County participated in a prostate examination campaign. Targeting these men, we collected the International Prostate Symptom Score (IPSS), medical history, demographic information, serum prostate-specific antigen, and prostate volume as measured by transrectal ultrasonography. The data for 599 participants were analyzed, excluding 180 men who had a possibility of prostate cancer. BPH was defined as an IPSS of 8 points or higher and a prostate volume of 25 mL or more.
RESULTS
The prevalence rate of BPH was 20.0%. The prevalence rate increased with age. There were 2 subjects (4.4%) in the age group of 40-49 years, 18 subjects (10.9%) in the age group of 50-59 years, 44 subjects (22%) in the age group of 60-69 years, and 56 subjects (26.6%) in the age group of over 70 years; this increase with age was statistically significant (p<0.001). In the BPH group, the average IPSS was 14.67+/-5.95, the average prostate volume was 37.04+/-11.71 g, and the average prostate-specific antigen value was 1.56+/-0.88 ng/mL. In the analysis of correlations between the epidemiologic factors and the risk of BPH, smoking was the only statistically significant factor.
CONCLUSIONS
The total prevalence rate of BPH in this study was 20.0%, which was a little lower than the rate reported in other cities or rural areas.

Keyword

Prevalence; Prostatic hyperplasia

MeSH Terms

Adult
Age Distribution
Aged
Community-Based Participatory Research
Cross-Sectional Studies
Humans
Male
Middle Aged
Multivariate Analysis
Prevalence
Prostate/ultrasonography
Prostate-Specific Antigen/blood
Prostatic Hyperplasia/*epidemiology
Republic of Korea/epidemiology
Rural Population/statistics & numerical data
Smoking/adverse effects
Prostate-Specific Antigen

Figure

• 

  Fig. 1 Flow chart of the selection of subjects for the study. TRUS, transrectal ultrasonography; IPSS, International Prostate Symptom Score; PSA, prostate-specific antigen.

Reference

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984; 132:474–479.

2. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991; 338:469–471.

3. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992; 148:1549–1557.

4. Taylor BC, Wilt TJ, Fink HA, Lambert LC, Marshall LM, Hoffman AR, et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology. 2006; 68:804–809.

5. Parsons JK, Mougey J, Lambert L, Wilt TJ, Fink HA, Garzotto M, et al. Lower urinary tract symptoms increase the risk of falls in older men. BJU Int. 2009; 104:63–68.

6. Engstrom G, Henningsohn L, Walker-Engstrom ML, Leppert J. Impact on quality of life of different lower urinary tract symptoms in men measured by means of the SF 36 questionnaire. Scand J Urol Nephrol. 2006; 40:485–494.

7. Bosch JL, Hop WC, Kirkels WJ, Schroder FH. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology. 1995; 46:3 Suppl A. 34–40.

8. Rhew HY, Koo JH, Cho SS, Kang JS, Lee CK, Kim JC, et al. The prevalence of BPH in Busan city over age 40. Korean J Urol. 2001; 42:223–227.

9. Chung TG, Chung J, Lee MS, Ahn H. Prevalence of benign prostatic hyperplasia in Jeong-Eup area: community-based study. Korean J Urol. 1999; 40:52–58.

10. Huh JS, Kim YJ, Kim SD. Prevalence of benign prostatic hyperplasia on Jeju Island: analysis from a cross-sectional community-based survey. World J Mens Health. 2012; 30:131–137.

11. Park HK, Park H, Cho SY, Bae J, Jeong SJ, Hong SK, et al. The prevalence of benign prostatic hyperplasia in elderly men in Korea: a community-based study. Korean J Urol. 2009; 50:843–847.

12. Blanker MH, Groeneveld FP, Prins A, Bernsen RM, Bohnen AM, Bosch JL. Strong effects of definition and nonresponse bias on prevalence rates of clinical benign prostatic hyperplasia: the Krimpen study of male urogenital tract problems and general health status. BJU Int. 2000; 85:665–671.

13. Jakobsen H, Torp-Pedersen S, Juul N. Ultrasonic evaluation of age-related human prostatic growth and development of benign prostatic hyperplasia. Scand J Urol Nephrol Suppl. 1988; 107:26–31.

14. Lee ES, Lee C, Kim Y, Shin Y. Estimation of benign prostatic hyperplasia prevalence in Korea: an epidemiological survey using International Prostatic Symptom Score (IPSS) in Yonchon county. Korean J Urol. 1995; 36:1345–1352.

15. Lee HL, Seo JW, Kim WJ. The prevalence of benign prostatic hyperplasia: community-based study in Chungbuk province. Korean J Urol. 1999; 40:1500–1505.

16. Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder Dysfunct Rep. 2010; 5:212–218.

17. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol. 2001; 54:935–944.

18. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond). 2005; 29:310–316.

19. Joseph MA, Harlow SD, Wei JT, Sarma AV, Dunn RL, Taylor JM, et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol. 2003; 157:906–914.

20. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006; 91:2562–2568.

21. Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol. 2007; 178:395–401.

22. Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol. 2009; 182:6 Suppl. S27–S31.

23. Kim Y, Seo S, Kwon O, Cho MS. Comparisons of dietary behavior, food intake, and satisfaction with food-related life between the elderly living in urban and rural areas. Korean J Nutr. 2012; 45:252–263.